Profile data is unavailable for this security.
About the company
Zelira Therapeutics Limited is an Australia-based biopharmaceutical company. The Company is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. It owns a portfolio of products and a pipeline of candidates undergoing clinical development positioned to enter global markets. It is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription (Rx) business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter (OTC) products. It has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The Company in partnership with SprinJeneCBD, introduced a full line of oral care products, including SprinJeneCBD toothpaste product, which is a hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilizing patented technology.
- Revenue in AUD (TTM)660.00
- Net income in AUD-3.63m
- Incorporated2003
- Employees8.00
- LocationZelira Therapeutics LtdLevel 3, 101 St Georges TerracePERTH 6000AustraliaAUS
- Phone+61 86558-0886
- Fax+61 86316-3337
- Websitehttps://zeliratx.com/home/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hydration Pharmaceuticals Co Ltd | 2.17m | -5.55m | 1.94m | -- | -- | 0.4504 | -- | 0.8914 | -0.022 | 0.0311 | 0.0077 | 0.01 | 0.3189 | 0.4291 | 1.99 | -- | -81.35 | -80.15 | -165.85 | -113.93 | 49.37 | 46.59 | -255.13 | -125.35 | 2.43 | -6.06 | 0.00 | -- | -25.48 | 1.58 | 21.50 | -- | -- | -- |
| Anatara Lifesciences Ltd | 0.00 | -1.95m | 3.45m | -- | -- | 4.38 | -- | -- | -0.0096 | -0.0096 | 0.00 | 0.0025 | 0.00 | -- | -- | -- | -138.64 | -87.11 | -204.84 | -106.65 | -- | -- | -- | -- | -- | -- | 0.4319 | -- | -- | -- | -34.69 | -- | -- | -- |
| Acrux Ltd | 4.53m | -5.95m | 6.16m | 43.00 | -- | 5.98 | -- | 1.36 | -0.0176 | -0.0176 | 0.0129 | 0.0025 | 0.5594 | -- | 1.36 | -- | -73.45 | -48.30 | -148.89 | -61.75 | 100.00 | -- | -131.29 | -101.52 | -- | -18.59 | 0.7804 | -- | -44.08 | 3.32 | -2.50 | -- | -54.56 | -- |
| Nutritional Growth Solutions Ltd | 3.00m | -3.98m | 7.33m | -- | -- | -- | -- | 2.45 | -0.0432 | -0.0432 | 0.0321 | -0.0117 | 3.26 | 4.05 | 33.35 | -- | -433.20 | -130.49 | -- | -187.56 | 26.70 | 40.32 | -132.89 | -143.99 | 0.1206 | -19.99 | -- | -- | -16.86 | 15.95 | -0.2074 | -- | -- | -- |
| Zelira Therapeutics Ltd | 660.00 | -3.63m | 7.44m | 8.00 | -- | -- | -- | 11,266.25 | -0.3172 | -0.3172 | 0.00006 | -0.3749 | 0.0002 | 0.0102 | 0.003 | -- | -118.74 | -50.35 | -- | -56.97 | -1,236.36 | 43.05 | -583,283.30 | -2,379.12 | 0.0244 | -6.50 | -- | -- | -99.30 | -77.07 | 90.08 | -- | -- | -- |
| Immuron Ltd | 7.29m | -5.22m | 9.80m | 7.00 | -- | 0.8698 | -- | 1.34 | -0.0226 | -0.0226 | 0.0316 | 0.0345 | 0.5675 | 1.50 | 4.40 | 1,041,000.00 | -40.62 | -27.84 | -49.64 | -30.60 | 65.39 | 70.18 | -71.58 | -182.34 | 4.19 | -- | 0.00 | -- | 48.63 | 23.67 | 24.81 | -- | -- | -- |
| Tissue Repair Ltd | 3.02m | -4.24m | 11.19m | -- | -- | 0.8041 | -- | 3.71 | -0.0701 | -0.0701 | 0.0499 | 0.2301 | 0.1777 | -- | 60.84 | -- | -24.96 | -24.25 | -26.50 | -25.27 | -- | -- | -140.49 | -518.54 | 22.40 | -- | 0.00 | -- | 236.85 | -- | -2.43 | -- | -- | -- |
| Calmer Co International Ltd | 8.03m | -3.99m | 12.23m | -- | -- | 6.33 | -- | 1.52 | -0.0015 | -0.0015 | 0.0029 | 0.0006 | 1.60 | 3.29 | 14.33 | -- | -79.73 | -109.82 | -171.17 | -197.50 | 42.49 | 41.18 | -49.69 | -128.71 | 1.22 | -11.32 | 0.5482 | -- | 88.48 | 59.99 | -7.13 | -- | 27.67 | -- |
| Epsilon Healthcare Ltd | 6.13m | -6.12m | 12.29m | -- | -- | -- | -- | 2.00 | -0.0164 | -0.0164 | 0.0167 | -0.0097 | 0.462 | -- | 4.95 | -- | -46.14 | -33.37 | -156.14 | -46.46 | 52.23 | 49.34 | -99.85 | -136.16 | 0.3775 | -3.92 | 1.67 | -- | -15.81 | 3.16 | -403.56 | -- | -32.83 | -- |
| Oncosil Medical Ltd | 1.26m | -15.10m | 12.85m | 2.00 | -- | 3.13 | -- | 10.18 | -1.37 | -1.37 | 0.1148 | 0.217 | 0.182 | -- | 2.18 | -- | -217.79 | -97.54 | -382.54 | -117.83 | -78.62 | -54.05 | -1,196.80 | -1,258.41 | -- | -146.89 | 0.022 | -- | 116.34 | -15.15 | -26.74 | -- | -6.31 | -- |
| Firebrick Pharma Ltd | 293.42k | -2.63m | 16.35m | -- | -- | 9.38 | -- | 55.73 | -0.0126 | -0.0126 | 0.0014 | 0.0069 | 0.1386 | 0.8696 | 0.4855 | -- | -124.44 | -98.41 | -143.50 | -109.28 | 35.72 | -- | -897.84 | -5,384.55 | 4.75 | -- | 0.00 | -- | 1,920.80 | -- | -124.04 | -- | -- | -- |
| TrivarX Ltd | 1.13m | -943.23k | 25.38m | 4.00 | -- | 1.08 | -- | 22.41 | -0.0018 | -0.0018 | 0.0023 | 0.0204 | 0.0923 | -- | -- | -- | -7.68 | -33.47 | -8.32 | -37.46 | -- | -- | -83.27 | -373.85 | -- | -27.05 | 0.0132 | -- | 26.38 | 3.89 | 34.25 | -- | 6.29 | -- |
